IN2005DE03350A - - Google Patents

Download PDF

Info

Publication number
IN2005DE03350A
IN2005DE03350A IN3350DE2005A IN2005DE03350A IN 2005DE03350 A IN2005DE03350 A IN 2005DE03350A IN 3350DE2005 A IN3350DE2005 A IN 3350DE2005A IN 2005DE03350 A IN2005DE03350 A IN 2005DE03350A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Marc Stadler
Stephan Seip
Hartwig Mueller
Anke Mayer-Bartschmid
Michael-Alexander Bruening
Jordi Benet-Buchholz
Hiroko Togame
Reiko Dodo
Peter Reinemer
Kevin Bacon
Kinji Fuchikami
Satoko Matsukawa
Klaus Urbahns
Original Assignee
Intermed Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermed Discovery Gmbh filed Critical Intermed Discovery Gmbh
Publication of IN2005DE03350A publication Critical patent/IN2005DE03350A/en
Publication of IN228043B publication Critical patent/IN228043B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
IN3350DE2005 2003-02-14 2004-02-06 IN228043B (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003495 2003-02-14
EP03007594 2003-04-02

Publications (2)

Publication Number Publication Date
IN2005DE03350A true IN2005DE03350A (hu) 2007-06-01
IN228043B IN228043B (hu) 2009-02-13

Family

ID=32870763

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3350DE2005 IN228043B (hu) 2003-02-14 2004-02-06

Country Status (16)

Country Link
US (2) US20060229353A1 (hu)
EP (1) EP1597262B1 (hu)
JP (1) JP4795931B2 (hu)
KR (1) KR20050098928A (hu)
CN (1) CN1845925B (hu)
AT (1) ATE448232T1 (hu)
AU (1) AU2004212296B2 (hu)
BR (1) BRPI0407234A (hu)
CA (1) CA2515940C (hu)
DE (1) DE602004024037D1 (hu)
ES (1) ES2336562T3 (hu)
HK (1) HK1096392A1 (hu)
IL (1) IL169897A0 (hu)
IN (1) IN228043B (hu)
MX (1) MX272108B (hu)
WO (1) WO2004071382A2 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1341414T3 (da) * 2000-11-16 2013-03-25 Univ California Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1638552B1 (en) * 2003-06-20 2011-03-02 Nereus Pharmaceuticals, Inc. Use of (3.2.0) heterocyclic compounds and analogs thereof for the treatment of cancer
US8217072B2 (en) 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
MXPA06012421A (es) 2004-04-30 2007-01-31 Nereus Pharmaceuticals Inc Compuestos de heterociclicos y metodos para utilizar los mismos.
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CN101133022A (zh) * 2004-07-12 2008-02-27 拜尔农作物科学股份公司 用作杀真菌剂和杀虫剂的取代的2-吡咯烷酮衍生物
KR20070086895A (ko) * 2004-12-03 2007-08-27 니리어스 파마슈티컬즈, 인코퍼레이션 〔3.2.0〕헤테로사이클릭 화합물 및 그의 유도체의사용방법
DK1830838T3 (da) * 2004-12-03 2013-01-21 Dana Farber Cancer Inst Inc Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
WO2006118973A2 (en) * 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
BRPI0709474A2 (pt) 2006-04-06 2011-07-12 Nerus Pharmaceuticals Inc sìntese total de salinosporamida a e seus análogos
US7824698B2 (en) 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
MX2010009860A (es) 2008-03-07 2010-09-30 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y sus analogos.
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
JP6251176B2 (ja) 2011-10-28 2017-12-20 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nae阻害物質に対する応答のバイオマーカー
CA2855368A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP2810066B1 (en) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
JP6486826B2 (ja) 2012-10-01 2019-03-20 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3339291A1 (en) 2016-12-22 2018-06-27 Vita Api Proteasome inhibiting ss-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
DK1341414T3 (da) * 2000-11-16 2013-03-25 Univ California Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter

Also Published As

Publication number Publication date
EP1597262A2 (en) 2005-11-23
EP1597262B1 (en) 2009-11-11
CN1845925A (zh) 2006-10-11
WO2004071382A2 (en) 2004-08-26
IN228043B (hu) 2009-02-13
ES2336562T3 (es) 2010-04-14
DE602004024037D1 (de) 2009-12-24
CN1845925B (zh) 2010-11-03
WO2004071382A3 (en) 2005-01-06
JP4795931B2 (ja) 2011-10-19
JP2006517934A (ja) 2006-08-03
CA2515940A1 (en) 2004-08-26
HK1096392A1 (en) 2007-06-01
MX272108B (es) 2009-11-25
US20110015248A1 (en) 2011-01-20
ATE448232T1 (de) 2009-11-15
MXPA05008478A (es) 2005-10-18
US20060229353A1 (en) 2006-10-12
CA2515940C (en) 2011-12-06
KR20050098928A (ko) 2005-10-12
AU2004212296B2 (en) 2010-06-17
AU2004212296A1 (en) 2004-08-26
IL169897A0 (en) 2007-07-04
BRPI0407234A (pt) 2006-01-31

Similar Documents

Publication Publication Date Title
BE2014C003I2 (hu)
BE2013C075I2 (hu)
BE2013C069I2 (hu)
BE2013C067I2 (hu)
BE2013C038I2 (hu)
BE2013C036I2 (hu)
BE2013C034I2 (hu)
BE2011C030I2 (hu)
JP2004219569A5 (hu)
IN2005DE03350A (hu)
BE2012C053I2 (hu)
JP2004221138A5 (hu)
JP2004216063A5 (hu)
AU2002318342A1 (hu)
AU2002331433A1 (hu)
AU2001282632A1 (hu)
AU2001256599A1 (hu)
AU2002311957A1 (hu)
AU2002359010A1 (hu)
AU2002316235A1 (hu)
AU2002316511A1 (hu)
AU2002239060A1 (hu)
AU2002321535A1 (hu)
AU2002322913A1 (hu)
AU2002245368A1 (hu)